Regeneron Pharmaceuticals, Inc (NASDAQ:REGN) traded at $490.28 at close of the session on Friday, May 30 and made a downward move of -19.01% on its previous day’s price.
Regeneron Pharmaceuticals, Inc has a market cap of $52.93 billion and is expected to release its quarterly earnings report in July. With its Forward Dividend at 1.76 and a yield of 0.36%, the company’s investors could be anxious for the REGN stock to gain ahead of the earnings release.
On the other hand, looking at the outlook for the REGN stock, short term indicators assign the stock an average of 100% Sell, while medium term indicators assign it an average of 100% Sell.
Based on estimates by 22 analysts, where scores have ranged from 1.00 for a strong buy to 5.00 for a strong sell, 1 have rated the Regeneron Pharmaceuticals, Inc (REGN) stock as a Hold, while 21 rate it as a Buy. 0 analyst(s) rate it as overweight while 0 of them rated it as underweight, whereas 0 suggest the stock as a Sell. The stock has an overall rating of Buy and investors could take advantage and scoop up stock of the company.
Looking further, we note that the PEG ratio for the REGN stock currently stands at 7.90, and the current price level is -15.44% off its SMA20 and -17.02% from its 50-day simple moving average. The RSI (14) is pointing at 32.32 while the volatility over the past week is 11.21% and jumps to 5.75% over the past one month. The beta value is 0.38, while the average true range (ATR) is currently pointing at 28.14. The average price target for the stock over the next 12 months is $850, with the estimates having a low of $695 and a high of $903. These price ends are -41.76% and -84.18% off the current price level respectively, although investors could be excited at the prospect of a -73.37% if the REGN share price touches on the median price of $850.
